Chirality-driven strong thioredoxin reductase inhibition

Area of Science:

• Medicinal Chemistry
• Biochemistry
• Drug Discovery

Background:

• Overexpression of thioredoxin reductase (TXNRD) is implicated in cancer development.
• Current TXNRD inhibitors often lack selectivity, leading to clinical toxicity.
• Developing selective inhibitors is crucial for targeted cancer therapy.

Purpose of the Study:

• To design highly selective chiral metal complexes as TXNRD inhibitors.
• To enhance non-covalent interactions within the TXNRD active site for improved drug compatibility.
• To overcome the selectivity challenges associated with traditional covalent inhibitors.

Main Methods:

• Synthesis and characterization of chiral metal complexes.
• In vitro assays to evaluate TXNRD inhibition.
• Computational modeling to understand drug-target interactions.
• Chirality manipulation to optimize drug conformation and binding.

Main Results:

• Chiral isomeric drugs demonstrated effective binding to the TXNRD active site.
• Drug-target interaction strength was modulated by chirality.
• The meso-configuration showed the highest number of non-covalent interactions and strongest inhibition.
• The strategy successfully avoided poor selectivity associated with covalent interactions.

Conclusions:

• Chiral metal complexes offer a novel approach for developing highly selective TXNRD inhibitors.
• Optimizing non-covalent interactions through conformational control enhances drug efficacy.
• This work provides insights into mechanisms for designing future proteinase inhibitors with improved selectivity and reduced toxicity.